Skip to main content
. 2019 Jul 12;121(4):312–317. doi: 10.1038/s41416-019-0521-7

Fig. 4.

Fig. 4

Benefit for OS with the addition of oxaliplatin to LV5FU2 in (a) all patients, (b) the MOSAIC low-risk patients, (c) the MOSAIC low-risk patients after CEA stratification, (d) the MOSAIC high-risk patients, and (e) the MOSAIC high-risk patients after CEA stratification. Figure 4 abbreviations: Ox: oxaliplatin;+ox: with oxaliplatin; Ox: without oxaliplatin